Pattern of multiple human papillomavirus infection and type competition: An analysis in healthy Chinese women aged 18-45 years

Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China

Immunogenicity and safety of an<i> ORF7</i>-deficient skin- attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2atrial

Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study

Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Head-to-head immunogenicity comparison of an<i> Escherichia</i> coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial

The epidemiology of varicella and effectiveness of varicella vaccine in Ganyu, China: a long-term community surveillance study

Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer

Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters

Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial

Safety and immunogenicity of an<i> Escherichia</i> coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial

Immunogenicity and safety of an<i> Escherichia</i> coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial

The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Prognosis of hepatitis E infection in patients with chronic liver disease: A meta-analysis

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

Comparison of HPV neutralizing and IgG antibodies in unvaccinated female adolescents

Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective

Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study

Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response

Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China

Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages

Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans

Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial

Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial

Immunogenicity of anEscherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study

Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial

Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years

Long-term Antibody Persistence After Hepatitis E Virus Infection and Vaccination in Dongtai, China

The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A population-based study

Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system

Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection

The prevalence of latent tuberculosis infection in rural Jiangsu, China

Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination

Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study

Modeling the long-term antibody response of a hepatitis E vaccine

Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial

Protective immunity against HEV

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine An open-label phase I clinical trial

Epidemiology of Zoonotic Hepatitis E: A Community-Based Surveillance Study in a Rural Population in China

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults

Safety of the hepatitis E vaccine for pregnant women: A preliminary analysis

Profile of Acute Infectious Markers in Sporadic Hepatitis E

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial